The Advisory Committee on Immunization Practices voted 12-2 to return the injectable nasal spray flu vaccine FluMist to the CDC list of recommended vaccines; HHS Secretary Alex Azar suggested that action on drug prices could happen without Congress; drug overdose deaths fell in 14 states.
The Advisory Committee on Immunization Practices (ACIP) voted 12-2 Wednesday to return the injectable nasal spray flu vaccine FluMist to market, although the move is likely too late for next winter’s flu season, Stat reported. The ACIP dropped FluMist from the list of recommended vaccines starting in the 2016-2017 flu season after CDC studies showed that the vaccine component targeting H1N1 flu viruses was not protective. The company that makes FluMist, MedImmune, later replaced the virus component.
HHS Secretary Alex Azar told an Indianapolis TV station that his department is working on additional proposals aimed at high drug prices, including some that could be enacted without Congress. The Hill reported on an interview he gave NBC affiliate WTHR in Indianapolis, where he talked about the administration’s budget proposals, including a cap on out-of-pocket spending for enrollees in Medicare’s prescription drug program and allowing up to 5 states to jointly negotiate Medicaid drug prices. Azar was not specific about additional actions, but said there were more proposals that “we'll move forward with on our own authority if we're able."
In a sign of hope in the opioid epidemic, provisional data from the CDC show that drug overdose deaths fell in 14 states during the 12-month period ending in July 2017, the Pew Charitable Trusts’ Stateline Daily reported. The reported drop in overdose deaths occurred in Wyoming, Utah, Washington, Alaska, Montana, Mississippi, Kansas, Rhode Island, Oregon, California, Tennessee, Massachusetts, Arizona, and Hawaii. However, several states saw overdose rates rise by more than 30%, most likely because of the increasing presence of fentanyl. Those states are Delaware, Florida, New Jersey, Ohio, and Pennsylvania, along with the District of Columbia.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen